Brief: Merck KGaA Confirms Late-Stage Discussions With Springworks Therapeutics On Potential Acquisition
24/04/2025 21:49
April 25 (Reuters) - Merck KGaA MRCG.DE: EQS-ADHOC: MERCK KGAA: MERCK CONFIRMS LATE-STAGE DISCUSSIONS WITH SPRINGWORKS THERAPEUTICS, INC. ON POTENTIAL ACQUISITION MERCK KGAA: PARTIES ARE IN DISCUSSION ON BASIS OF A PRICE OF AROUND USD 47 PER SHARE MERCK KGAA: NO FINAL DECISION HAS BEEN TAKEN AND NO LEGALLY BINDING AGREEMENT HAS BEEN ENTERED INTO Source text: ID:nEQ3NsrHga Further company coverage: MRCG.DE ((reuters.briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN